[Driving: What is the relevance and usability of the Reisberg scale in 2023?] / Conduite automobile : Quelle est la pertinence et l'utilité de l'échelle de Reisberg en 2023 ?

The publication of the decree on the care of people with neurocognitive disorders brought to the fore the Reisberg's Global Deterioration Scale, a scale that only few clinicians use in memory centers or in geriatric. This scale has a number of limitations, not least of which is that it is obsolete, since it does not take into account disease advances in scientific knowledge with biomarkers. Consequently, the stages evoked no longer correspond to current descriptions. Moreover, it only concerns Alzheimer's disease, whereas in our practice we encounter other neurodegenerative pathologies. Even if we decide to use another global assessment scale, such as the Clinical Dementia Rating or the Functional Assessment Staging, they cannot replace a personalized assessment. Indeed, it is important to stress that this decree does not take into account the relevance of personalized assessments using, for example, neuropsychological tests to estimate driving ability. A personalized assessment accompanied by a real-life driving test would be preferable than a score on a global scale. This article therefore presents the Global Deterioration Scale, highlighting its unsuitability for assessing whether or not to continue driving.

[Support and guidance in driving for patients with (or suspected of having) Alzheimer's disease or related diseases: position paper]. / Recommandations pour l'accompagnement et l'orientation pour la conduite des patients atteints (ou suspectés) d'une maladie d'Alzheimer ou de maladies apparentées : consensus des sociétés savantes françaises.

New ministerial decree restricts driving motorized vehicles for patients with Alzheimer's disease and related disorders. Reisberg stage 3, threshold used to contraindicate driving, appears to correspond to a mild stage of major neurocognitive impairment. A single scale gives an idea of the level of risk but does not provide a holistic assessment. The aim of this consensus is to put forward recommendations from several French learned societies for individualized cognitive assessments to minimize the risks associated with driving and its cessation. Fitness to drive should be raised at the earliest stages of the diagnostic process, and regularly throughout the follow-up. Consult a registered doctor is recommended to all patients wishing to continue driving. All documents must be given to the patient only. An alternative must always be offered to patients who are recommended a modal shift.

Why and how to evaluate driving abilities in patients with neurodegenerative diseases?

Many studies have shown that individuals with neurodegenerative diseases are at risk of being involved in a traffic accident. However, driving is critical for social integration and independence in daily life. The lack of consensus and a standardised assessment of driving abilities in these patients is problematic. This article summarises the various multidisciplinary evaluations proposed, their limits and the societal issues raised by such an evaluation. Several theoretical neuropsychological models have attempted to describe the cognitive processes involved in car driving. Moreover, several studies into neurodegenerative diseases have sought to determine which alterations to cognitive functions best explain driving errors. In this article, we describe the relationships between neuropsychological performance and driving abilities for the most frequent neurodegenerative disorders. It appears that a full neuropsychological assessment is necessary to accurately determine which patients are at risk of dangerous driving. In particular, cognitive impairments in attention, visual-spatial abilities, executive functions, and/or information processing speed appear to be the most likely to be involved in driving errors.

[Why and how evaluating driving abilities in patients with neurodegenerative diseases?] / Pourquoi et comment évaluer l'aptitude à la conduite automobile chez les patients souffrant de maladies neurodégénératives ?

Many studies have shown that individuals with neurodegenerative diseases are a risk factor for being involved in a traffic accident. However, driving is critical for social integration and independence in daily life. Lack of consensus and standardized assessment of driving abilities in these patients is problematic. This article summarizes the various multidisciplinary evaluations proposed, their limits, and the societal issues raised by such an evaluation. Several neuropsychological theoretical models have attempted to describe the cognitive processes involved in car driving. Moreover, several studies have sought to determine which cognitive functions are impaired in distinct disorders and best explained driving errors. We here describe the relationships between neuropsychological performance and driving abilities for the most frequent neurodegenerative disorders. It appears that a full neuropsychological assessment is necessary to determine accurately which patients are at risk of dangerous driving. In particular, cognitive impairments in attention, visual-spatial abilities, executive functions, and/or information processing speed appear to be the most likely involved in driving errors.